Table 1:
Patient Baseline Demographics.
| Characteristic | ITT Cohort (N = 36) |
HRR-Intact (N = 14) |
HRR-Deficient (N = 16) |
|---|---|---|---|
|
| |||
| Age, years (median [IQR]) | 70 (63, 76) | 75 (71, 81) | 67 (61, 72) |
| PSA, ng/mL (median [IQR]) | 26 (13, 114) | 22 (12, 66) | 25 (12, 114) |
| Race | |||
| Black or African American (n [%]) | 1 (2.8%) | 1 (7.1%) | 0 (0%) |
| Native Hawaiian or Other Pacific Islander (n [%]) | 1 (2.8%) | 0 (0%) | 1 (6.2%) |
| White (n [%]) | 25 (69%) | 9 (64%) | 12 (75%) |
| Unknown/Not Reported (n [%]) | 9 (25%) | 4 (29%) | 3 (19%) |
| ECOG performance status | |||
| 0 (n [%]) | 24 (67%) | 9 (64%) | 12 (75%) |
| 1 (n [%]) | 11 (31%) | 4 (29%) | 4 (25%) |
| 2 (n [%]) | 1 (2.8%) | 1 (7.1%) | 0 (0%) |
| Prior Docetaxel in hormone-sensitive setting (n [%]) | 9 (25%) | 2 (14%) | 5 (31%) |
| Prior Abiraterone (n [%])* | 14 (39%) | 5 (36%) | 7 (44%) |
| Prior Enzalutamide (n [%])* | 7 (19%) | 3 (21%) | 1 (6.2%) |
| Prior Abiraterone and Enzalutamide (n [%]) | 11 (31%) | 5 (36%) | 5 (31%) |
| Prior Radium-223 (n [%]) | 12 (33%) | 5 (36%) | 3 (19%) |
| Prior Sipuleucel-t (n [%]) | 13 (36%) | 5 (36%) | 6 (38%) |
*
Received only the single prior novel hormonal agent indicated (i.e. did not receive both abiraterone and enzalutamide)